Patents by Inventor Christopher Graham Raphael Parsons
Christopher Graham Raphael Parsons has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220193035Abstract: Provided herein are methods of use of indole derivative compounds for reversal of amyloid ? toxicity in amyloid ?-associated diseases.Type: ApplicationFiled: April 23, 2020Publication date: June 23, 2022Applicant: Galimedix Therapeutics, Inc.Inventors: Christopher Graham Raphael. Parsons (Deceased), Gerhard Rammes, Hermann Russ, Andrew L Pearlman
-
Patent number: 9717772Abstract: Methods for the prevention and treatment of ocular disorders, in particular glaucoma, through blocking the toxic effects of ?-amyloid (A?) derivatives, pharmaceutical compositions for effecting such prevention and interval treatment thereof.Type: GrantFiled: June 20, 2013Date of Patent: August 1, 2017Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Hermann Russ, Wojciech Danysz, Christopher Graham Raphael Parsons
-
Patent number: 8288549Abstract: The invention relates to quinoline derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.Type: GrantFiled: September 30, 2009Date of Patent: October 16, 2012Assignee: Merz Pharma GmbH & Co. KGaAInventors: Markus Henrich, Angela Bauer, Jens Nagel, Meik Sladek, Christopher Graham Raphael Parsons, Wojciech Danysz, Valerjans Kauss, Jevgenijs Rozhkovs, Igors Starchenkovs, Dina Trifanova
-
Publication number: 20110212956Abstract: Substituted pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2, Y3, Y4 represent N or C—, whereby at least two of the groups Y1 to Y4 represent a carbon atom, R1 represents chloro or bromo, R2 to R7 represent e.g. hydrogen, methyl or ethyl; and R10 and R11 independently represent e.g. hydrogen or C1-C6alkyl, are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.Type: ApplicationFiled: May 3, 2011Publication date: September 1, 2011Applicant: MERZ PHARMA GmbH & CO. KGaAInventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Graham Raphael Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaitas, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
-
Publication number: 20110190342Abstract: The invention relates to quinoline derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.Type: ApplicationFiled: September 30, 2009Publication date: August 4, 2011Inventors: Markus Henrich, Angela Bauer, Jens Nagel, Meik Sladek, Christopher Graham Raphael Parsons, Wojciech Danysz, Valerjans Kauss, Jevgenijs Rozhkovs, Igos Starchenkovs, Dina Trifanova
-
Patent number: 7985753Abstract: Substituted pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2, Y3, Y4 represent N or C—, whereby at least two of the groups Y1 to Y4 represent a carbon atom, R1 represents chloro or bromo, R2 to R7 represent e.g. hydrogen, methyl or ethyl; and R10 and R11 independently represent e.g. hydrogen or C1-C6alkyl, are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.Type: GrantFiled: August 3, 2007Date of Patent: July 26, 2011Assignee: MERZ PHARMA GmbH & Co. KGaAInventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Graham Raphael Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaits, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
-
Patent number: 7947689Abstract: The invention relates to pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2 and Y3 independently are e.g. CR10, NH, S or O, whereby at least one of Y1, Y2 and Y3 represents CR10; R1 represents chloro or bromo; R2, R3, R4, R5, R6 and R7 represent e.g. hydrogen or C1-C6-alkyl, and R10 represents e.g. hydrogen, halogen or phenyl; which are potent mGluR5 modulators and are e.g. useful for the treatment of various neurological disorders.Type: GrantFiled: August 3, 2007Date of Patent: May 24, 2011Assignee: Merz Pharma GmbH & Co. KGaAInventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Graham Raphael Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaits, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
-
Publication number: 20100298442Abstract: Certain 1-aminoalkylcyclohexanes are systematically-active 5HT3 and nicotinic receptor antagonists and are useful in the inhibition of progression of or alleviation of conditions resulting from disturbances of serotoninergic or nicotinergic transmission giving them a wide range of utility in the treatment of CNS-disorders. Pharmaceutical compositions thereof for such purpose and method of making same, as well as a method-of-treating conditions which are alleviated by the employment of a 5HT3 or neuronal nicotinic receptor antagonist.Type: ApplicationFiled: July 26, 2010Publication date: November 25, 2010Applicant: MERZ PHARMA GmbH & CO. KGaAInventors: Christopher Graham Raphael Parsons, Wojciech Danysz, Markus Gold, Ivars Kalvinsh, Valerjans Kauss, Aigars Jirgensons
-
Patent number: 7598384Abstract: The invention relates to tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR antagonists and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.Type: GrantFiled: February 25, 2005Date of Patent: October 6, 2009Assignee: Merz Pharma GmbH & Co. KGAAInventors: Aigars Jirgensons, Christopher Graham Raphael Parsons, Ieva Jaunzeme, Ivars Kalvinsh, Markus Henrich, Maksims Vanejevs, Tanja Weil, Valerjans Kauss, Wojciech Danysz
-
Patent number: 7550482Abstract: The invention relates to ethynyl-substituted tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.Type: GrantFiled: August 24, 2005Date of Patent: June 23, 2009Assignee: Merz Pharma GmbH & Co. KGAAInventors: Valerjans Kauss, Ieva Jaunzeme, Aigars Jirgensons, Ivars Kalvinsh, Maksims Vanejevs, Markus Henrich, Wojciech Danysz, Claudia Jatzke, Christopher Graham Raphael Parsons, Tanja Weil
-
Publication number: 20090081259Abstract: The present invention relates to the treatment of individuals diagnosed with multiple sclerosis, emotional lability or pseudobulbar affect comprising administering to said individual an effective amount of a 1-aminocyclohexane derivative, namely memantine or neramexane.Type: ApplicationFiled: August 5, 2008Publication date: March 26, 2009Applicant: MERZ PHARMA GMBH & CO. KGAAInventors: Jeffrey Jonas, Allison Mann, Christopher Graham Raphael Parsons, Wojciech Danysz
-
Publication number: 20080039476Abstract: The invention relates to pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2 and Y3 independently are e.g. CR10, NH, S or O, whereby at least one of Y1, Y2 and Y3 represents CR10; R1 represents chloro or bromo; R2, R3, R4, R5, R6 and R7 represent e.g. hydrogen or C1-C6-alkyl, and R10 represents e.g. hydrogen, halogen or phenyl; which are potent mGluR5 modulators and are e.g. useful for the treatment of various neurological disorders.Type: ApplicationFiled: August 3, 2007Publication date: February 14, 2008Applicant: MERZ PHARMA GMBH & CO. KGAAInventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Graham Raphael Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaits, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
-
Publication number: 20070299113Abstract: The invention relates to imidazothiazole derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR modulators and are therefore useful for the control and prevention of various disorders, including acute and/or chronic neurological disorders.Type: ApplicationFiled: June 22, 2007Publication date: December 27, 2007Applicant: MERZ PHARMA GMBH & CO. KGAAInventors: Ivars Kalvinsh, Larisa Kaulina, Valerjans Kauss, Ronalds Zemribo, Wojciech Danysz, Markus Henrich, Christopher Graham Raphael Parsons, Tanja Weil, Elina Erdmane
-
Patent number: 7022729Abstract: Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes which are systemically-active as NMDA, 5HT3, and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.Type: GrantFiled: March 21, 2003Date of Patent: April 4, 2006Assignee: Merz Pharma GmbH & Co. KGAAInventors: Christopher Graham Raphael Parsons, Markus Henrich, Wojciech Danysz, Ivars Kalvinsh, Valerjans Kauss, Aigars Jirgensons, Markus Gold, Maksims Vanejevs
-
Patent number: 6828462Abstract: Unsaturated 1-Amino-alkylcyclohexane compounds which are systemically-active as NMDA, 5HT3, and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.Type: GrantFiled: November 6, 2002Date of Patent: December 7, 2004Assignee: Merz Pharma GmbH & Co. KGAAInventors: Markus Henrich, Wojciech Danysz, Christopher Graham Raphael Parsons, Ivars Kalvinsh, Valerjans Kauss, Aigars Jirgensons, Markus Gold
-
Publication number: 20040034055Abstract: Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexanes which are systemically-active as NMDA, 5HT3, and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.Type: ApplicationFiled: March 21, 2003Publication date: February 19, 2004Applicant: MERZ PHARMA GMBH & CO. KGAAInventors: Christopher Graham Raphael Parsons, Markus Henrich, Wojciech Danysz, Ivars Kalvinsh, Valerjans Kauss, Aigars Jirgensons, Markus Gold, Maksims Vanejevs
-
Publication number: 20030166634Abstract: Unsaturated 1-Amino-alkylcyclohexane compounds which are systemically-active as NMDA, 5HT3, and nicotinic receptor antagonists, pharmaceutical compositions comprising the same, method of preparation thereof, and method of treating CNS disorders which involve disturbances of glutamatergic, serotoninergic, and nicotinic transmission, treating immunomodulatory disorders, and antimalaria, antitrypanosomal, anti-Borna virus, anti-HSV and anti-Hepatitis C virus activity.Type: ApplicationFiled: November 6, 2002Publication date: September 4, 2003Inventors: Markus Henrich, Wojciech Danysz, Christopher Graham Raphael Parsons, Ivars Kalvinsh, Valerjans Kauss, Aigars Jirgensons, Markus Gold
-
Patent number: 6071966Abstract: Certain 1-aminoalkylcyclohexanes are systemically-active uncompetitive NMDA receptor antagonists having rapid blocking/unblocking kinetics and strong voltage-dependency and are therefore useful in the alleviation of conditions resulting from disturbances of glutamatergic transmission giving them a wide range of utility in the treatment of CNS disorders involving the same, as well as in non-NMDA indications, due to their immunomodulatory, antimalarial, anti-Borna virus, and anti-Hepatitis C activities and utilities. Pharmaceutical compositions thereof and a method-of-treating conditions which are alleviated by the employment of an NMDA receptor antagonist, as well as the aforementioned non-NMDA indications, and a method for the preparation of the active 1-aminoalkylcyclohexane compounds involved.Type: GrantFiled: August 27, 1998Date of Patent: June 6, 2000Assignee: Merz + Co. GmbH & Co.Inventors: Markus Gold, Wojciech Danysz, Christopher Graham Raphael Parsons, Ivars Kalvinsh, Valerjans Kauss, Aigars Jirgensons
-
Patent number: 6034134Abstract: Certain 1-aminoalkylcyclohexanes are systemically-active uncompetitive NMDA receptor antagonists having rapid blocking/unblocking kinetics and strong voltage-dependency and are therefore useful in the alleviation of conditions resulting from disturbances of glutamatergic transmission giving them a wide range of utility in the treatment of CNS disorders involving the same, as well as in non-NMDA indications, due to their immunomodulatory, antimalarial, anti-Borna virus, and anti-Hepatitis C activities and utilities. Pharmaceutical compositions thereof and a method-of-treating conditions which are alleviated by the employment of an NMDA receptor antagonist, as well as the aforementioned non-NMDA indications, and a method for the preparation of the active 1-aminoalkylcyclohexane compounds involved.Type: GrantFiled: August 27, 1998Date of Patent: March 7, 2000Assignee: Merz + Co. GmbH & Co.Inventors: Markus Gold, Wojciech Danysz, Christopher Graham Raphael Parsons, Ivars Kalvinsh, Valerjans Kauss, Aigars Jirgensons
-
Patent number: 5776935Abstract: Pyridyl-phtalazin diones having the following formula: ##STR1## wherein R1 and R2 are selected from the group consisting of hydrogen, halogen, and methoxy or wherein R1 and R2 together form methylenedioxy, and pharmaceutically-acceptable salts thereof, and pharmaceutical compositions containing an effective glycine.sub.B antagonistic amount thereof, are useful in combatting neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission in a living animal, including a human, in need thereof.Type: GrantFiled: July 25, 1996Date of Patent: July 7, 1998Assignee: Merz & Co. GmbH & Co.Inventors: Wojciech Danysz, Markus Gold, Ivars Kalvinsh, Christopher Graham Raphael Parsons, Irene Piskunova, Eugene Rozhkov